Catalent is the leading global provider of advanced drug delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

With over 85 years’ industry experience, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and reliable global clinical and commercial supply.

One of over 40 sites in Catalent’s network, the company’s 250,000 square foot facility in Swindon is home to the company’s proprietary Zydis ® orally disintegrating tablet (ODT) technology.

The facility produces over one billion ODTs annually and employs more than 600 people. ODT technology is used in many over-the-counter consumer health treatments and prescription medicines, and helps make each dose easier to take and effective, without the need for water.

Catalent is pleased to support the TechSwindon campaign in its goal of promoting innovation and celebrating the skills and people based in the town.

Catalent continues to make ongoing investments in its people and facilities, and in 2019, the company announced it is to invest $27 million to commercialize its next-generation ODT technology, Zydis Ultra, which will allow for larger doses to be delivered with similar dosing benefits.

For information about joining Catalent, visit

Get Involved